What Has Been the Growth of the Exocrine Pancreatic Insufficiency EPI Therapeutics And Diagnostics Market So Far?
The exocrine pancreatic insufficiency epi therapeutics and diagnostics market has seen considerable growth due to a variety of factors.
• The market size for EPI (exocrine pancreatic insufficiency) therapeutics and diagnostics has seen robust growth of late. The market is projected to increase from a value of $5.69 billion in 2024 to $6.17 billion in 2025, representing a compound annual growth rate (CAGR) of 8.4%.
Factors such as higher incidence of underlying conditions, progress in diagnostic instrument technology, advancements in pharmaceuticals, and increased access to global healthcare services have all contributed to the growth during the historical period.
What Are the Future Growth Projections for the Exocrine Pancreatic Insufficiency EPI Therapeutics And Diagnostics Market?
The exocrine pancreatic insufficiency epi therapeutics and diagnostics market is expected to maintain its strong growth trajectory in upcoming years.
• Anticipated to witness robust growth in the forthcoming years, the market size for therapeutics and diagnostics related to exocrine pancreatic insufficiency (EPI) is projected to rise to $8.32 billion by 2029 at a compound annual growth rate (CAGR) of 7.8%.
Factors propelling growth during the forecast period include advancements in telemedicine and remote monitoring, data analytics and artificial intelligence, patient education and support, in addition to shifts in regulatory policies and reimbursement guidelines. The period is also expected to usher in major market trends such as customized treatment strategies, the inception of new therapies, minimally intrusive diagnostics, and cooperative care models.
What Are The Core Factors Supporting Growth In The Exocrine Pancreatic Insufficiency EPI Therapeutics And Diagnostics Market?
The uptick in diabetes diagnoses is anticipated to fuel the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. Diabetes, a chronic metabolic disorder marked by long-term hyperglycemia, results from the body's inability to sufficiently produce insulin or effectively utilize the insulin it does produce. Treating EPI with pancreatic enzyme replacement therapy (PERT) improves nutrient absorption in diabetic individuals with EPI and enhances their glycemic control. The National Health Service (NHS England), a UK-based publicly funded healthcare organization, revealed that in June 2024, the number of people in England with pre-diabetes identified by the NHS had risen to 3,615,330 by 2023, an 18% rise from 3,065,825 in 2022. Likewise, among those below 40, cases spiked nearly 25%, increasing from 173,166 in 2022 to 216,440 in 2023. Therefore, the swelling number of diabetic individuals is spurring the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. The escalating incidence of gastrointestinal disorders is predicted to stimulate the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market's growth. Gastrointestinal diseases, comprising several health conditions that impact the digestive system, are prevalent. Exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics are vital for managing these gastrointestinal diseases by substituting deficient enzymes and thereby aiding digestion. As per Crohn's and Colitis Canada, a non-profit organization, more than 322,600 Canadians were believed to be living with inflammatory bowel diseases (IBD) in June 2023, roughly 0.82% of the populace. Predictions suggest that the prevalence of IBD will continue and approximately 470,000 Canadians or about 1.1% of the population or 1 in 91 people will be living with IBD by 2035. Therefore, the increasing occurrence of gastrointestinal diseases is likely to stimulate the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market's growth.
What Are The Major Segments Within The Global Exocrine Pancreatic Insufficiency EPI Therapeutics And Diagnostics Market?
The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market covered in this report is segmented –
1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach
2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning
3) By Drug Type: Generic, Branded
4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels
5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users
Subsegments:
1) By Nutritional Management: Dietary Modifications, Nutritional Supplements
2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations
3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs
Pre-Book The Exocrine Pancreatic Insufficiency EPI Therapeutics And Diagnostics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Exocrine Pancreatic Insufficiency EPI Therapeutics And Diagnostics Market?
Key players in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are opting for strategic partnerships for technological enhancement and to extend their market influence. A strategic partnership refers to a cooperative tie-up between two or more entities pooling their resources, know-how, and endeavors to attain shared goals. An example of this occurred in February 2023 when Codexis, Inc., a protein engineering company from the US, and Nestlé Health Science, a Swiss nutrition science company, unveiled preliminary results from their Phase 1 clinical examination of CDX-7108, a potential therapy for EPI. The findings from this Phase 1 study lay the groundwork for potential future studies, which could significantly enrich the therapeutic choices for EPI patients.
Who Are the Key Players In The Exocrine Pancreatic Insufficiency EPI Therapeutics And Diagnostics Market?
Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are:
• Pfizer Inc.
• Merck & Co. Inc.
• Janssen Pharmaceuticals Inc.
• AbbVie Inc.
• Novartis AG
• Sanofi S.A.
• AstraZeneca PLC
• Abott Laboratories
• Medtronic PLC
• Solvay S.A.
• Laboratory Corporation of America Holdings (Labcorp)
• Organon group of companies Metagenics LLC
• Allergan PLC
• Chiesi Farmaceutici S.p.A.
• Codexis Inc.
• Nordmark Arzneimittel GmbH & Co. KG
• ChiRhoClin Inc.
• Digestive Care Inc.
• Alcresta Therapeutics Inc.
• Vivus Inc.
• Cilian AG
• Bioserv Diagnostics Gmbh
• Anthera Pharmaceuticals Inc.
• Aptalis Pharma Inc.
• First Wave BioPharma Inc.
• EagleBiosciences Inc.
• ScheBo Biotech AG.
What Is The Most Dominant Region In The Exocrine Pancreatic Insufficiency EPI Therapeutics And Diagnostics Market?
North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2024. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
